For research use only. Not for therapeutic Use.
LY3509754 (IL-17A inhibitor 1) is a IL-17A inhibitor, with IC50 values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells[1].
LY3509754 (example 24) possesses high oral bioavailability (F=107%)[1].
| Catalog Number | I044434 |
| CAS Number | 2452464-73-0 |
| Synonyms | N-[(S)-(4,4-difluorocyclohexyl)-[7-[(1S)-2-methoxy-1-[(4S)-2-oxo-4-(trifluoromethyl)imidazolidin-1-yl]ethyl]imidazo[1,2-b]pyridazin-2-yl]methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide |
| Molecular Formula | C24H27F5N8O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H27F5N8O4/c1-12-19(35-41-34-12)21(38)33-20(13-3-5-23(25,26)6-4-13)15-9-37-18(31-15)7-14(8-30-37)16(11-40-2)36-10-17(24(27,28)29)32-22(36)39/h7-9,13,16-17,20H,3-6,10-11H2,1-2H3,(H,32,39)(H,33,38)/t16-,17+,20+/m1/s1 |
| InChIKey | MVWVCLAORBNXSD-UWVAXJGDSA-N |
| SMILES | CC1=NON=C1C(=O)NC(C2CCC(CC2)(F)F)C3=CN4C(=N3)C=C(C=N4)C(COC)N5CC(NC5=O)C(F)(F)F |
| Reference | [1]. COATES DAVID ANDREW, et al. IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS. Patent WO2020146194. |
